Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2013 1
2014 4
2015 2
2016 2
2017 1
2018 3
2019 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.
Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B, Hallek M, Döhner H, Hillmen P, van Oers M, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T; European Research Initiative on CLL (ERIC). Pospisilova S, et al. Leukemia. 2012 Jul;26(7):1458-61. doi: 10.1038/leu.2012.25. Epub 2012 Feb 2. Leukemia. 2012. PMID: 22297721 Review.
Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
Pospisilova S, Sutton LA, Malcikova J, Tausch E, Rossi D, Montserrat E, Moreno C, Stamatopoulos K, Gaidano G, Rosenquist R, Ghia P; European Research Initiative on CLL (ERIC). Pospisilova S, et al. Haematologica. 2016 Mar;101(3):263-5. doi: 10.3324/haematol.2015.139246. Haematologica. 2016. PMID: 26928246 Free PMC article. No abstract available.
Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification.
Sutton LA, Hadzidimitriou A, Baliakas P, Agathangelidis A, Langerak AW, Stilgenbauer S, Pospisilova S, Davis Z, Forconi F, Davi F, Ghia P, Rosenquist R, Stamatopoulos K; European Research Initiative on CLL (ERIC). Sutton LA, et al. Haematologica. 2017 Jun;102(6):968-971. doi: 10.3324/haematol.2017.165605. Haematologica. 2017. PMID: 28566340 Free PMC article. No abstract available.
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova J, Agathangelidis A, Davis Z, Tausch E, Stalika E, Kantorova B, Mansouri L, Scarfò L, Cortese D, Navrkalova V, Rose-Zerilli MJ, Smedby KE, Juliusson G, Anagnostopoulos A, Makris AM, Navarro A, Delgado J, Oscier D, Belessi C, Stilgenbauer S, Ghia P, Pospisilova S, Gaidano G, Campo E, Strefford JC, Stamatopoulos K, Rosenquist R; European Research Initiative on CLL (ERIC). Baliakas P, et al. Leukemia. 2015 Feb;29(2):329-36. doi: 10.1038/leu.2014.196. Epub 2014 Jun 19. Leukemia. 2015. PMID: 24943832
Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond.
Rosenquist R, Rosenwald A, Du MQ, Gaidano G, Groenen P, Wotherspoon A, Ghia P, Gaulard P, Campo E, Stamatopoulos K; European Research Initiative on CLL (ERIC) and the European Association for Haematopathology (EAHP). Rosenquist R, et al. Haematologica. 2016 Sep;101(9):1002-9. doi: 10.3324/haematol.2015.134510. Haematologica. 2016. PMID: 27582569 Free PMC article. Review.
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia.
Baliakas P, Moysiadis T, Hadzidimitriou A, Xochelli A, Jeromin S, Agathangelidis A, Mattsson M, Sutton LA, Minga E, Scarfò L, Rossi D, Davis Z, Villamor N, Parker H, Kotaskova J, Stalika E, Plevova K, Mansouri L, Cortese D, Navarro A, Delgado J, Larrayoz M, Young E, Anagnostopoulos A, Smedby KE, Juliusson G, Sheehy O, Catherwood M, Strefford JC, Stavroyianni N, Belessi C, Pospisilova S, Oscier D, Gaidano G, Campo E, Haferlach C, Ghia P, Rosenquist R, Stamatopoulos K; European Research Initiative on CLL (ERIC). Baliakas P, et al. Haematologica. 2019 Feb;104(2):360-369. doi: 10.3324/haematol.2018.195032. Epub 2018 Sep 27. Haematologica. 2019. PMID: 30262567 Free PMC article.
High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies.
Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, Moreno C, Robak T, Stilgenbauer S, Montserrat E; European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT). Dreger P, et al. Blood. 2018 Aug 30;132(9):892-902. doi: 10.1182/blood-2018-01-826008. Epub 2018 Jul 11. Blood. 2018. PMID: 29997221 Free article. Review.
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, Kimby E, Michallet M, Moreno C, Stilgenbauer S, Montserrat E; European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT). Dreger P, et al. Blood. 2014 Dec 18;124(26):3841-9. doi: 10.1182/blood-2014-07-586826. Epub 2014 Oct 9. Blood. 2014. PMID: 25301705 Free PMC article. Review.
Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia.
te Raa GD, Malcikova J, Pospisilova S, Trbusek M, Mraz M, Garff-Tavernier ML, Merle-Béral H, Lin K, Pettitt AR, Merkel O, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC). te Raa GD, et al. Leuk Lymphoma. 2013 Aug;54(8):1849-53. doi: 10.3109/10428194.2013.796058. Epub 2013 Jun 24. Leuk Lymphoma. 2013. PMID: 23614766 Review.
15 results